---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-088021"
form_type: "8-K"
ticker: "VSTM"
cik: "0001526119"
company_name: "Verastem, Inc."
filed_at: "2025-09-08T23:59:59+00:00"
generated_at: "2026-05-17T07:34:36.289675+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Verastem reports $2.1M net product revenue from AVMAPKI FAKZYNJA launch in first 6 weeks

## Summary
- AVMAPKI FAKZYNJA co-pack approved May 8, 2025 for KRAS-mutant recurrent LGSOC; $2.1M net revenue in first six weeks.
- RAMP 201 trial showed 44% ORR and median DoR 3.3-31.1 months for approved combination.
- RAMP 205 dose level 1 in 1L metastatic pancreatic cancer achieved 83% confirmed ORR (10/12).
- VS-7375 (KRAS G12D inhibitor) Phase 1/2a trial dosed first patient in U.S.; Fast Track designation granted.
- RAMP 301 confirmatory trial enrollment on track for completion by end of 2025; IDMC recommendation expected Q4 2025.

## SEC filing metadata
- accession: 0001104659-25-088021
- form_type: 8-K
- ticker: VSTM
- cik: 0001526119
- company_name: Verastem, Inc.
- filed_at: 2025-09-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1526119/000110465925088021/0001104659-25-088021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1526119/000110465925088021/tm2525447d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-088021
- JSON: https://secwatch.observer/filing/0001104659-25-088021.json
- Plain text: https://secwatch.observer/filing/0001104659-25-088021.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.